A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 40
- Population
- ALL · 40 Years
- Duration
- 2026-03-01 to 2027-10-01
- Intervention
- Exercise; Usual Care
- Comparator
- Middle-age adults with MASLD receiving usual care
- Outcomes measured
- Change in hepatic fat content — Change from baseline to 12 weeks; Change in liver inflammation and fibrosis — Change from baseline to 12 weeks; Change in liver stiffness — Change from baseline to 12 weeks.; Change in Enhanced Liver Fibrosis (ELF) Score — Change from baseline to 12 weeks; Change in Pro-C3 serum levels — Change from baseline to 12 weeks; Change in NIS4 serum biomarker of liver fibrosis — Change from baseline to 12 weeks; Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF) — Change from baseline to 12 weeks; Change in visceral adipose tissue — Change from baseline to 12 weeks; Change in pancreatic fat content — Change from baseline to 12 weeks; Change in abdominal subcutaneous adipose tissue — Change from baseline to 12 weeks; Change in abdominal intermuscular fat content — Change from baseline to 12 weeks; Change in abdominal intramuscular fat content — Change from baseline to 12 weeks; Change in abdominal skeletal muscle tissue — Change from baseline to 12 weeks; Change in values of fasting glucose — Change from baseline to 12 weeks; Change in values of HbA1c — Change from baseline to 12 weeks; Change in values of fasting insulin — Change from baseline to 12 weeks; Change in levels of mean glucose (Continuous Glucose Monitoring) — Change from baseline to 12 weeks.; Change in fasting lipid profile — Change from baseline to 12 weeks; Change in alkaline phosphatase — Baseline to 12 weeks; Change in alanine aminotransferase (ALT) — Baseline to 12 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Exercise · 100%Title contains controlled term: exercise. Abstract contains controlled term: exercise. Source terminology contains: exercise. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.